Sept 21 (Reuters) - Provention Bio Inc
* Provention Bio announces licensing agreements with Janssen for two clinical-stage immunology assets
* Provention Bio says entered into agreements with Janssen Pharmaceutica NV, Janssen Sciences Ireland UC to in-license 2 clinical-stage assets
* Provention Bio -PRV-6527 to be studied in phase 2a POC clinical trial in Crohn’s disease,for which Provention anticipates initiating enrollment in H1 2018 Source text for Eikon:
